The White House said it’s adding Boehringer Ingelheim’s Jentadueto/Jentadueto XR and Striverdi Respimat to the cash-pay TrumpRx site — with prices Jentadueto $55 and Striverdi $35 (vs. list prices of about $525 and ~$276), creating a new option for patients who are uninsured or paying out of pocket.

The move

• The White House announced Friday that three drugs are being added to TrumpRx: Jentadueto and Jentadueto XR (Type 2 diabetes) and Striverdi Respimat (COPD).

• TrumpRx cash prices start around $55 for the diabetes drugs (listed ~ $525) and about $35 for Striverdi (listed ~ $276), per the administration.

• Boehringer Ingelheim becomes the ninth drugmaker participating, according to the White House.

Why it Matters for Care

• For uninsured patients — and for insured patients who choose to pay cash — the posted prices could materially change the “can they fill it today?” conversation at the bedside and in discharge planning.

• Jentadueto has a generic that is often cheaper; Ben Link (46brooklyn) noted patients may pay ~$25–$35 for generic at the counter, making TrumpRx “still competitive” but not necessarily the lowest-cost route.

• Because TrumpRx discounts can’t be used with insurance or count toward deductibles, clinicians and staff may need to steer patients toward the right lane (cash-pay vs. plan benefits vs. generics) to avoid surprise costs.

Between the Lines

• HHS official Chris Klomp said TrumpRx was never intended for people with health insurance — signaling the platform is positioned as a targeted cash-pay tool, not a systemwide drug-pricing fix.

• The political incentive is clear: visible, concrete “price drops” on branded drugs — even when similar discounts may exist elsewhere (e.g., GoodRx) and even when generics undercut brand cash prices.

• Limited scope remains a constraint: fewer than 60 drugs are listed, and the site’s impact is hard to measure because the White House won’t disclose usage.

What to Watch

• Whether TrumpRx expands beyond a small formulary — and which therapeutic areas (and manufacturers) are next.

• Adoption: KFF found ~1/3 of people who take prescription drugs had heard at least something about TrumpRx; only 7% had visited to compare prices (16% among GLP-1 users).

• Downstream effects in clinics and pharmacies: more cash-pay fills, more requests for “price checks,” and more switching between brand, generic, and discount channels as patients try to manage out-of-pocket costs.

Source: NBC News Health